Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: Do we still need consolidative radiotherapy?

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3710-3717

  Vargo, John A ^a   Gill, Beant S ^a   Balasubramani, Goundappa K ^b   Beriwal, Sushil ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; EARLY CANCER; EDUCATION; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; SOCIOECONOMICS; TREATMENT OUTCOME; ADJUVANT RADIOTHERAPY; AGED; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL;

ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84942346433     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.7654     Document Type: Article

References (28)

1. Zelenetz AD, Wierda WG, Abramson JS, et al: Non-Hodgkin's lymphoma, version 4.2014. J Natl Compr Canc Netw 12:1282-1303, 2014
2. Tilly H, Vitolo U, Walewski J, et al: Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 23:78-82, 2012
3. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998
4. Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032-3038, 2004
5. Reyes F, Lepage E, Ganem G, et al: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205, 2005
6. Bonnet C, Fillet G, Mounier N, et al: CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007
7. Phan J, Mazloom A, Medeiros LJ, et al: Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28:4170-4176, 2010
8. Marcheselli L, Marcheselli R, Bari A, et al: Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 52:1867-1872, 2011
9. Dabaja BS, Vanderplas AM, Crosby-Thompson AL, et al: Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer 121:1032-1039, 2015
10. Held G, Murawski N, Ziepert M, et al: Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 32:1112-1118, 2014
11. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al: Prognostic significance of maximum tumour (bulk) diameter in young patients with goodprognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 9:435-444, 2008
12. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
13. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
14. Giobbie-Hurder A, Gelber RD, Regan MM: Challenges of guarantee-time bias. J Clin Oncol 31:2963-2969, 2013
15. D'Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281, 1998
16. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Toronto, ON, Canada, Academic Press, 1977, pp 19-74
17. Cole SR, Hernan MA: Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168:656-664, 2008
18. Held G, Zeynalova S, Murawski N, et al: Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol 31:4115-4122, 2013
19. Ballonoff A, Rusthoven K, Schwer A, et al: Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: A Suveillance, Epidemiology, and End Results analysis. Int J Radiat Oncol Biol Phys 72:1465-1471, 2008
20. Lowry, Smith P, Qian W, et al: Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomized phase III trial. Radiother Oncol 100:86-92, 2011
21. Illidge T, Spetch L, Yahalom J, et al: Modern radiation therapy for nodal non-Hodgkin lymphoma target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89:49-58, 2011
22. Olszewski AJ, Desai A: Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue. Int J Radiat Oncol Biol Phys 88:642-649, 2014
23. Tao L, Foran JM, Clarke CA, et al: Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood 123:3553-3562, 2014
24. Lee B, Hoktepe O, Hay K, et al: Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia. Oncologist 19:283-290, 2014
25. Olszewski AJ, Shrestha R, Castillo JJ: Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: Analysis of the National Cancer Data Base. J Clin Oncol 33:625-633, 2015
26. Pugh TJ, Ballanoff A, Rusthoven KE, et al: Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: A Surveillance, Epidemiology, and End Results analysis. Int J Radiat Oncol Biol Phys 76:845-849, 2010
27. Flowers CR, Fedewa SA, Chen AY, et al: Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev 21:1520-1530, 2012
28. Jagsi R, Abrahamse P, Hawley ST, et al: Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer 118:333-341, 2012